BioPontis Aims To Bridge Pharma-Academic Divide
This article was originally published in The Pink Sheet Daily
Executive Summary
The investment group hopes to make VC-like returns from its business model, which directly addresses gaps in the traditional academic and biopharma industry relationships.
You may also be interested in...
BioPontis Aims To Bridge "Valley Of Death"
BioPontis Alliance, a two-year old investment group, has been set up as a virtual network with the aim of introducing a new model for bridging the "valley of death" funding gap for early stage translational research. Its mission: to get more great science translated out of academia, say founders.
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
With funds and firms closing, a new reality awaits those who survive until the next economic upswing. Some of the elements are already in place, such as VCs' willingness to take capped returns and exits via risk-sharing contingency-based acquisitions. The emphasis on capital efficiency may change the types of companies VCs can afford to back, and corporate funds are now a vital part of biotech venture, especially in the early stages.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.